A Pilot Study of Galunisertib (LY2157299) Plus Stereotactic Body Radiotherapy (SBRT) in Patients With Advanced Hepatocellular Carcinoma (HCC)
Phase of Trial: Phase I
Latest Information Update: 27 Jul 2017
At a glance
- Drugs Galunisertib (Primary)
- Indications Liver cancer
- Focus Adverse reactions
- 20 Jul 2017 Planned End Date changed from 1 Dec 2018 to 1 Sep 2018.
- 20 Jul 2017 Planned primary completion date changed from 1 Dec 2018 to 1 Sep 2018.
- 30 Mar 2017 Status changed from not yet recruiting to recruiting.